2008
DOI: 10.1007/s00432-008-0367-5
|View full text |Cite
|
Sign up to set email alerts
|

Identification of triosephosphate isomerase as an anti-drug resistance agent in human gastric cancer cells using functional proteomic analysis

Abstract: These results provide new MDR-related protein candidates, which are differentially expressed in the MDR cell line and its parental cell line including TPI, which may participate in the VCR-mediated MDR in human gastric cancer. Upregulation of TPI expression could partially reverse multidrug-resistant phenotype of SGC7901/VCR, which suggests that TPI may be an anti-drug resistance agent in gastric cancer and the candidate target to develop novel therapeutics for better treatment of gastric cancer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
20
0

Year Published

2009
2009
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 27 publications
(20 citation statements)
references
References 24 publications
0
20
0
Order By: Relevance
“…Conversely, tau can have an effect on TPI, triggering its functional loss and subsequently facilitating neurodegenerative disease development [214]. Many studies elucidated that TPI was also involved in tumorigenesis and anti-drug resistance of cancer cells [215217]. …”
Section: Oxidation Protein-adductsmentioning
confidence: 99%
“…Conversely, tau can have an effect on TPI, triggering its functional loss and subsequently facilitating neurodegenerative disease development [214]. Many studies elucidated that TPI was also involved in tumorigenesis and anti-drug resistance of cancer cells [215217]. …”
Section: Oxidation Protein-adductsmentioning
confidence: 99%
“…They develop neurodegenerative disorders, cardiomyopathy, muscle disorders, and, less often, hemolytic anemia [11]. Furthermore, triosephosphate isomerase is capable of converting drug-resistant stomach cancer cells to sensitive ones [13], which improves the chemotherapy efficacy and makes the enzyme a potential target for new antitumor drugs. …”
Section: Introductionmentioning
confidence: 99%
“…Triosephosphate isomerase (TPI) (spot 3, Table 1), which catalyzes the reversible interconversion of the triose phosphate isomers, dihydroxyacetone phosphate and d -glyceraldehyde 3-phosphate, is one of the glycolysis enzymes that improves drug resistance and survival of cancer cells [44]. TPI up-regulation has been found in melanoma, pancreatic and colon cancer [45–47]; TPI overexpression correlates well with the enhanced invasion ability of cancer [47].…”
Section: Resultsmentioning
confidence: 99%